ArticleCancer medicine2025
Effect of Fluence Rate on Tumor Tissue Damage in IRDye700DX-Based Photoimmunotherapy.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Fluence Rate on Tumor Tissue Damage in IRDye700DX-Based Photoimmunotherapy.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveIRDye700DX-based photoimmunotherapy (IR700-based PIT) is a newly developed cancer phototherapy using an antibody-photosensitizer conjugate (APC). The APC for IR700-based PIT (mAb-IR700) bound to target molecules on the membrane of cancer cells causes rapid cell necrosis following light irradiation. It is thus reasonable to consider that the light irradiation in IR700-based PIT influences its therapeutic effect. However, the relationship between the therapeutic effect and light irradiation conditions has remained unclear. This study aimed to investigate the influence of the light dose and fluence rate on IR700-based PIT efficacy.
methodsWe first examined the effect on cytotoxicity in vitro. Epidermal growth factor receptor (EGFR)-overexpressing A431 tumor cells were incubated with an mAb-IR700 targeting EGFR and exposed to light. Next, the effect on tumor tissue damage was examined in vivo. A431 cells and two human epidermal growth factor receptor 2-overexpressing tumor cell lines were subcutaneously grafted into BALB/c nude mice. The mice were exposed to light 1 day after mAb-IR700 injection.
resultsThe number of propidium iodide-positive dead cells in vitro increased in a light dose-dependent manner but was not influenced by fluence rate. One day after light irradiation in vivo revealed that the tumor tissue damage increased in a light dose-dependent manner but decreased with increasing fluence rate in the three tumor-grafted animal models. Furthermore, tumor growth inhibition data after 24 days from IR700-based PIT was consistent with the acute tissue-damage data.
conclusionThis study demonstrates that fluence rate as well as light dose impacts in vivo anti-tumor effect, and the effects on tumor microenvironment might be responsible for the discrepancy from in vitro results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.